icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2015
50th Annual Meeting of the European
Association for the Study of the Liver
Vienna, Austria  April 22-26
Back grey_arrow_rt.gif
 
 
 
EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR +/- RBV FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV G1, G4 OR G6 INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/RBV: C-EDGE TREATMENT-EXPERIENCED
 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna, Austria
 
Paul Kwo1, Ed Gane2, Cheng-Yuan Peng3, Brian Pearlman4, John Vierling5, Lawrence Serfaty6, Maria Buti7, Stephen Shafran8, Paul Stryszak9, Li Lin9, Jacqueline Gress9, Michael Robertson9, Janice Wahl9, Eliav Barr9, Barbara Haber9 1Indiana University, Indianapolis, IN, USA; 2Auckland Clinical Studies, Grafton, Auckland, New Zealand; 3China Medical University Hospital, Taichung, Taiwan; 4Center for Hepatitis C, Atlanta Medical Center, Atlanta, GA, USA; 5Baylor College of Medicine, Baylor-St. Luke's Medical Center, Houston, TX, USA; 6Service d'Hépatologie, Hôpital Saint-Antoine, APHP, UPMC Paris 6, Paris, France; 7Hospital General Universitari Vall d'Hebron, Barcelona, Spain; 8University of Alberta, Edmonton, Alberta, Canada; 9Merck & Co. Inc., Kenilworth, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif